-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
2021 is about to come to an end, and this year's Internet buzzword summary activities have also begun to surface
.
In this year’s Internet buzzwords, there are also some words that apply to the development of the pharmaceutical industry this year.
Let’s take a look at it~ From three Internet hot words, look at the development of the pharmaceutical industry in 2021 (Source: Pharmaceutical Network) "Liver" "The word "liver" originally meant spending a lot of time and energy playing games in the internet buzzwords, but now it can mean spending a lot of energy in a short period of time to do things
.
This year, Chinese pharmaceutical companies are "innovating the liver" by continuously increasing R&D investment
.
Since 2021, under the pressure of centralized procurement and other pharmaceutical policy environments, China's pharmaceutical companies have been enthusiastic about R&D and continue to develop in the direction of innovation
.
Data show that in the first three quarters of this year, more than 80% of the A-share listed pharmaceutical companies have increased their total R&D investment compared to the same period last year
.
Among them, six companies have invested more than 1 billion yuan in R&D, including Hengrui Pharmaceuticals, Fosun Pharma, Mindray Medical, Junshi Bio, Shanghai Pharmaceuticals, and Kelun Pharmaceuticals.
The R&D investment of these six companies in the first three quarters was 4.
142 billion.
Yuan, 2.
414 billion yuan, 1.
629 billion yuan, 1.
423 billion yuan, 1.
367 billion yuan, 1.
189 billion yuan, compared with the same period last year, an increase of 23.
86%, 28.
55%, 20.
64%, 17.
56%, 31.
38% and 18.
97% respectively
.
In addition, there are nearly 70 pharmaceutical companies that have invested more in R&D in the first nine months of this year than in the whole of last year.
Among them, the total R&D investment in the first three quarters of this year was 5,110,600 yuan, compared with 50,100 yuan in the whole year of last year.
, The number of doublings is amazing
.
The industry pointed out that judging from the intensity of "liver innovation" of pharmaceutical companies this year, the past model of "light R&D and focus on sales" is changing, which will help companies find new growth points, but pay attention not to blindly pursue innovation.
The commercialization prospects of new products and the market demand should be rationally viewed on the potential for new drugs to increase the valuation of companies
.
"Emo" Since the beginning of this year, the internet hot word "emo" has been out of circles frequently.
Contemporary young people often use emo to describe their emotions
.
The current meaning of this hot word is similar to "mourning", "sadness" and "depression"
.
In 2021, with the continuous advancement of new medical reforms such as the normalization of centralized procurement and medical insurance negotiations, the price reduction of medicines and consumables has become a major trend.
The pressure on pharmaceutical companies under the control of medical insurance fees has doubled and they have also fallen into an emo state
.
In order to bid farewell to emo, this year some pharmaceutical companies including VTR, Dongyang Sunshine, Zhendong Pharmaceuticals, GSK and other pharmaceutical companies have made the decision to divest non-core assets, by selling assets, equity and even technology and product transfers to focus on their main businesses, revitalize funds, and seek new opportunities.
Development opportunities
.
In addition, the out-of-hospital market has increasingly become the focus of the deployment of pharmaceutical companies, including Pfizer, AstraZeneca, Bayer and other large foreign pharmaceutical companies have begun to increase their deployment outside the grassroots market team; domestic pharmaceutical companies are also actively expanding the grassroots market to seize more More market share
.
In addition to pharmaceutical companies, pharmacy continued to emo this year.
During the year, domestic and foreign pharmaceutical companies including Pfizer and Yiling Pharmaceuticals successively announced the abolition of sales teams.
The 3 million pharmaceutical representatives behind them are facing a painful period of transformation
.
"New Year's Day" "New Year's Day" is often used in Internet buzzwords to indicate that netizens have encountered something happy and worth celebrating
.
Looking back on 2021, local innovative drug companies have continued to rise, and domestic innovative drugs continue to be marketed and approved, and good news is coming to the international stage.
Isn’t it a "Chinese New Year" atmosphere? According to the "Annual Report 2020 on the Current Status of Clinical Trials in New Drug Registration in China" published by CDE on November 10, China has registered a total of 2,602 clinical trials in 2020, an overall increase of 9.
1% compared with 2019
.
Among them, clinical trials of innovative drugs accounted for more than half
.
In 2021, the momentum of innovative drugs will remain strong, and there will continue to be news of new drugs being approved for marketing
.
According to data, there are 27 innovative drugs that have passed the review in January-September, including cyclopofol injection, enovirin tablets, hytropopaethanolamine tablets, hypertropin tablets, syvotinib tablets, Blockbuster drugs such as Levoornidazole Phosphate Disodium for Injection are better than last year in terms of quantity and variety, covering many urgently needed clinical treatment drugs in the fields of tumors, vaccines, rare diseases, etc.
.
Innovative Chinese medicines have also continued to receive news.
For example, on November 26, the State Food and Drug Administration approved the listing and registration of 3 innovative Chinese medicines: Xuanqijiangu Tablets, Qizhiyishen Capsules, and Kunxinning Granules.
Apply
.
It is reported that in November, the application for registration of Yinqiao Qingre Tablets was approved, and a total of 4 innovative Chinese medicines were approved for listing within the month
.
In the context of fierce competition in the domestic market, local pharmaceutical companies are also continuing to go overseas, and 2021 can be described as violent
.
According to incomplete statistics in the industry, since the beginning of 2021, the number of overseas authorized transactions by local pharmaceutical companies has exceeded 30, involving pharmaceutical companies such as BeiGene, Rongchang Biotechnology, and Livzon Group.
For these pharmaceutical companies, their independently developed products have successfully exported overseas , I believe it is not an exaggeration to describe it as "Chinese New Year"
.
.
In this year’s Internet buzzwords, there are also some words that apply to the development of the pharmaceutical industry this year.
Let’s take a look at it~ From three Internet hot words, look at the development of the pharmaceutical industry in 2021 (Source: Pharmaceutical Network) "Liver" "The word "liver" originally meant spending a lot of time and energy playing games in the internet buzzwords, but now it can mean spending a lot of energy in a short period of time to do things
.
This year, Chinese pharmaceutical companies are "innovating the liver" by continuously increasing R&D investment
.
Since 2021, under the pressure of centralized procurement and other pharmaceutical policy environments, China's pharmaceutical companies have been enthusiastic about R&D and continue to develop in the direction of innovation
.
Data show that in the first three quarters of this year, more than 80% of the A-share listed pharmaceutical companies have increased their total R&D investment compared to the same period last year
.
Among them, six companies have invested more than 1 billion yuan in R&D, including Hengrui Pharmaceuticals, Fosun Pharma, Mindray Medical, Junshi Bio, Shanghai Pharmaceuticals, and Kelun Pharmaceuticals.
The R&D investment of these six companies in the first three quarters was 4.
142 billion.
Yuan, 2.
414 billion yuan, 1.
629 billion yuan, 1.
423 billion yuan, 1.
367 billion yuan, 1.
189 billion yuan, compared with the same period last year, an increase of 23.
86%, 28.
55%, 20.
64%, 17.
56%, 31.
38% and 18.
97% respectively
.
In addition, there are nearly 70 pharmaceutical companies that have invested more in R&D in the first nine months of this year than in the whole of last year.
Among them, the total R&D investment in the first three quarters of this year was 5,110,600 yuan, compared with 50,100 yuan in the whole year of last year.
, The number of doublings is amazing
.
The industry pointed out that judging from the intensity of "liver innovation" of pharmaceutical companies this year, the past model of "light R&D and focus on sales" is changing, which will help companies find new growth points, but pay attention not to blindly pursue innovation.
The commercialization prospects of new products and the market demand should be rationally viewed on the potential for new drugs to increase the valuation of companies
.
"Emo" Since the beginning of this year, the internet hot word "emo" has been out of circles frequently.
Contemporary young people often use emo to describe their emotions
.
The current meaning of this hot word is similar to "mourning", "sadness" and "depression"
.
In 2021, with the continuous advancement of new medical reforms such as the normalization of centralized procurement and medical insurance negotiations, the price reduction of medicines and consumables has become a major trend.
The pressure on pharmaceutical companies under the control of medical insurance fees has doubled and they have also fallen into an emo state
.
In order to bid farewell to emo, this year some pharmaceutical companies including VTR, Dongyang Sunshine, Zhendong Pharmaceuticals, GSK and other pharmaceutical companies have made the decision to divest non-core assets, by selling assets, equity and even technology and product transfers to focus on their main businesses, revitalize funds, and seek new opportunities.
Development opportunities
.
In addition, the out-of-hospital market has increasingly become the focus of the deployment of pharmaceutical companies, including Pfizer, AstraZeneca, Bayer and other large foreign pharmaceutical companies have begun to increase their deployment outside the grassroots market team; domestic pharmaceutical companies are also actively expanding the grassroots market to seize more More market share
.
In addition to pharmaceutical companies, pharmacy continued to emo this year.
During the year, domestic and foreign pharmaceutical companies including Pfizer and Yiling Pharmaceuticals successively announced the abolition of sales teams.
The 3 million pharmaceutical representatives behind them are facing a painful period of transformation
.
"New Year's Day" "New Year's Day" is often used in Internet buzzwords to indicate that netizens have encountered something happy and worth celebrating
.
Looking back on 2021, local innovative drug companies have continued to rise, and domestic innovative drugs continue to be marketed and approved, and good news is coming to the international stage.
Isn’t it a "Chinese New Year" atmosphere? According to the "Annual Report 2020 on the Current Status of Clinical Trials in New Drug Registration in China" published by CDE on November 10, China has registered a total of 2,602 clinical trials in 2020, an overall increase of 9.
1% compared with 2019
.
Among them, clinical trials of innovative drugs accounted for more than half
.
In 2021, the momentum of innovative drugs will remain strong, and there will continue to be news of new drugs being approved for marketing
.
According to data, there are 27 innovative drugs that have passed the review in January-September, including cyclopofol injection, enovirin tablets, hytropopaethanolamine tablets, hypertropin tablets, syvotinib tablets, Blockbuster drugs such as Levoornidazole Phosphate Disodium for Injection are better than last year in terms of quantity and variety, covering many urgently needed clinical treatment drugs in the fields of tumors, vaccines, rare diseases, etc.
.
Innovative Chinese medicines have also continued to receive news.
For example, on November 26, the State Food and Drug Administration approved the listing and registration of 3 innovative Chinese medicines: Xuanqijiangu Tablets, Qizhiyishen Capsules, and Kunxinning Granules.
Apply
.
It is reported that in November, the application for registration of Yinqiao Qingre Tablets was approved, and a total of 4 innovative Chinese medicines were approved for listing within the month
.
In the context of fierce competition in the domestic market, local pharmaceutical companies are also continuing to go overseas, and 2021 can be described as violent
.
According to incomplete statistics in the industry, since the beginning of 2021, the number of overseas authorized transactions by local pharmaceutical companies has exceeded 30, involving pharmaceutical companies such as BeiGene, Rongchang Biotechnology, and Livzon Group.
For these pharmaceutical companies, their independently developed products have successfully exported overseas , I believe it is not an exaggeration to describe it as "Chinese New Year"
.
